Japan Approves Pfizer's Xalacom For Glaucoma
This article was originally published in PharmAsia News
Japan's Ministry of Health, Labor and Welfare Jan. 20 approved Pfizer's Xalacam (latanoprost/ timolol) eye drops for glaucoma and ocular hypertension. Latanoprost and timolol work together to decrease eye pressure in a once-daily formulation that decreases pressure for 24 hours. Xalacom is the first combo glaucoma drug approved in Japan. (Click here for more - Japanese language)
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.